Naringenin inhibits osteoclastogenesis through modulation of helper T cells-secreted IL-4

Area of Science:

• Biochemistry
• Immunology
• Cell Biology

Background:

• Naringenin (NAR), a natural flavanone, exhibits diverse pharmacological effects.
• Osteoclastogenesis, driven by RANKL, is crucial for bone resorption and diseases like osteoporosis.
• Understanding NAR's impact on T cell differentiation and osteoclast activity is key.

Purpose of the Study:

• To elucidate the protective mechanisms of Naringenin against RANKL-induced osteoclastogenesis.
• To investigate NAR's effects on T cell subsets and osteoclast bone resorption.
• To determine the role of IL-4 in NAR-mediated suppression of osteoclast activity.

Main Methods:

• Flow cytometry to analyze CD4+ T cell subsets (Th1, Th17, Th2, Treg).
• TRAP staining, pit formation assays, and F-actin ring staining to assess osteoclast function.
• Quantitative PCR and Western blot to analyze osteoclast-specific gene and protein expression.

Main Results:

• NAR treatment shifted T cell populations towards Th2 and Treg cells, while decreasing Th1 and Th17 cells.
• NAR significantly inhibited osteoclast formation, bone resorption pit areas, and F-actin ring development.
• NAR downregulated key osteoclast markers (cathepsin K, c-Fos, DC-STAMP, NFATc1, TRAP, V-ATPase d2) at mRNA and protein levels.
• The inhibitory effects of NAR were dependent on IL-4, as neutralizing IL-4 abolished these effects.

Conclusions:

• Naringenin suppresses RANKL-induced osteoclastogenesis and bone resorption.
• NAR exerts its protective effects by promoting IL-4 release from T cells.
• NAR represents a potential therapeutic agent for bone-related disorders characterized by excessive osteoclast activity.